Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Isofol Medical AB ( (SE:ISOFOL) ) just unveiled an announcement.
Isofol Medical AB has announced a fully guaranteed Rights Issue of approximately SEK 85 million, with an additional over-allotment issue of SEK 10 million proposed to accommodate potential oversubscription. This financial move is aimed at securing funds for an expanded Phase II study, with significant support from existing shareholders and strategic partner Solasia Pharma K.K., highlighting confidence in Isofol’s strategic direction and the potential of its lead drug, arfolitixorin.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company based in Gothenburg, Sweden, primarily focused on developing cancer treatments. The company is known for its work on arfolitixorin, a drug aimed at enhancing the efficacy of chemotherapy in cancer patients.
YTD Price Performance: -16.31%
Average Trading Volume: 342,680
Current Market Cap: SEK300.1M
See more data about ISOFOL stock on TipRanks’ Stock Analysis page.